Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy. 1998

S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
Department of Clinical Viro-Immunology, CLB Sanquin Blood Supply Foundation and Laboratory for Clinical and Experimental Immunology, Academic Medical Centre, Amsterdam, The Netherlands.

OBJECTIVE Highly active antiretroviral therapy (HAART) induces a decline in viral load and a biphasic increase in peripheral blood CD4+ T-cell counts in HIV-infected patients. To evaluate the effect of HAART on T-cell receptor (TCR) diversity of repopulating naive and memory CD4+ T cells, complementarity determining region 3 (CDR3) spectratyping was performed. METHODS For four patients treated with HAART, CD45RO+ (memory) and CD45RA+ (naive) CD4+ T cells were isolated from peripheral blood leukocyte samples obtained 1 week before, 1-2 months after, and 9-11 months after start of treatment. METHODS CDR3 regions were amplified by TCR-BV-specific nested PCR from CD4+ T-cell subsets. CDR3 size distributions and single-strand conformation polymorphism profiles were compared as an indication for TCR diversity. RESULTS Increasing blood CD4+ T-cell counts during the first 2 months of treatment coincided with increased perturbation of CDR3 patterns in CD4+ T-cell subsets, suggesting an early oligoclonal repopulation. At later timepoints, CDR3 size diversity increased when T-cell counts did not substantially decrease. Memory and naive CD4+ T cells generally showed comparable levels of perturbation. CONCLUSIONS Diversity of the TCR repertoire reflected biphasic T-cell repopulation during HAART, compatible with initial redistribution and later CD4+ T-cell production. Sustained elevation of T-cell counts will in principle result in restoration of TCR diversity.

UI MeSH Term Description Entries
D007135 Immunoglobulin Variable Region That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions. Variable Region, Ig,Variable Region, Immunoglobulin,Framework Region, Immunoglobulin,Fv Antibody Fragments,Fv Fragments,Ig Framework Region,Ig Variable Region,Immunoglobulin Framework Region,Immunoglobulin Fv Fragments,Immunoglobulin V,Antibody Fragment, Fv,Antibody Fragments, Fv,Fragment, Fv,Fragment, Fv Antibody,Fragment, Immunoglobulin Fv,Fragments, Fv,Fragments, Fv Antibody,Fragments, Immunoglobulin Fv,Framework Region, Ig,Framework Regions, Ig,Framework Regions, Immunoglobulin,Fv Antibody Fragment,Fv Fragment,Fv Fragment, Immunoglobulin,Fv Fragments, Immunoglobulin,Ig Framework Regions,Ig Variable Regions,Immunoglobulin Framework Regions,Immunoglobulin Fv Fragment,Immunoglobulin Variable Regions,Regions, Immunoglobulin Variable,Variable Regions, Ig,Variable Regions, Immunoglobulin
D007137 Immunoglobulin alpha-Chains The class of heavy chains found in IMMUNOGLOBULIN A. They have a molecular weight of approximately 58 kDa and contain about 470 amino acid residues arranged in four domains and an oligosaccharide component bound covalently to their Fc fragment constant region. Ig alpha Chains,Immunoglobulins, alpha-Chain,Immunoglobulin alpha-Chain,alpha-Chain Immunoglobulins,alpha-Immunoglobulin Heavy Chain,alpha-Immunoglobulin Heavy Chains,Chains, Ig alpha,Heavy Chain, alpha-Immunoglobulin,Heavy Chains, alpha-Immunoglobulin,Immunoglobulin alpha Chain,Immunoglobulin alpha Chains,Immunoglobulins, alpha Chain,alpha Chain Immunoglobulins,alpha Chains, Ig,alpha Immunoglobulin Heavy Chain,alpha Immunoglobulin Heavy Chains,alpha-Chain, Immunoglobulin,alpha-Chains, Immunoglobulin
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016693 Receptors, Antigen, T-Cell, alpha-beta T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules. Antigen Receptors, T-Cell, alpha-beta,T-Cell Receptors alpha-Chain,T-Cell Receptors beta-Chain,T-Cell Receptors, alpha-beta,TcR alpha-beta,Antigen T Cell Receptor, alpha Chain,Antigen T Cell Receptor, beta Chain,Receptors, Antigen, T Cell, alpha beta,T Cell Receptors, alpha beta,T-Cell Receptor alpha-Chain,T-Cell Receptor beta-Chain,T-Cell Receptor, alpha-beta,T Cell Receptor alpha Chain,T Cell Receptor beta Chain,T Cell Receptor, alpha beta,T Cell Receptors alpha Chain,T Cell Receptors beta Chain,TcR alpha beta,alpha-Chain, T-Cell Receptor,alpha-Chain, T-Cell Receptors,alpha-beta T-Cell Receptor,alpha-beta T-Cell Receptors,alpha-beta, TcR,beta-Chain, T-Cell Receptor,beta-Chain, T-Cell Receptors
D017493 Leukocyte Common Antigens High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain two FIBRONECTIN TYPE III DOMAINS and possess cytoplasmic protein tyrosine phosphatase activity, which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. Leukocyte common antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons. Antigens, CD45,CD45 Antigens,CD45R Antigens,CD45RA Antigens,CD45RO Antigens,Protein Tyrosine Phosphatase, Receptor Type, C,2H4 Antigens,B220 Antigen,B220 Antigens,CD45 Antigen,CD45R0 Antigens,CD45RB Antigens,CD45RCAntigens,L-CA Antigens,Leukocyte Common Antigen,T200 Antigens,Antigen, B220,Antigen, CD45,Antigen, Leukocyte Common,Antigens, 2H4,Antigens, B220,Antigens, CD45R,Antigens, CD45R0,Antigens, CD45RA,Antigens, CD45RB,Antigens, CD45RO,Antigens, L-CA,Antigens, Leukocyte Common,Antigens, T200,L CA Antigens
D018807 Polymorphism, Single-Stranded Conformational Variation in a population's DNA sequence that is detected by determining alterations in the conformation of denatured DNA fragments. Denatured DNA fragments are allowed to renature under conditions that prevent the formation of double-stranded DNA and allow secondary structure to form in single stranded fragments. These fragments are then run through polyacrylamide gels to detect variations in the secondary structure that is manifested as an alteration in migration through the gels. SSCP,Single-Stranded Conformational Polymorphism,Conformational Polymorphism, Single-Stranded,Conformational Polymorphisms, Single-Stranded,Polymorphism, Single Stranded Conformational,Polymorphisms, Single-Stranded Conformational,Single Stranded Conformational Polymorphism,Single-Stranded Conformational Polymorphisms

Related Publications

S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
September 2009, The Journal of antimicrobial chemotherapy,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
May 2002, Blood,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
September 2002, Antiviral therapy,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
December 2000, Proceedings of the National Academy of Sciences of the United States of America,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
May 2012, The Journal of infectious diseases,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
March 2001, Blood,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
November 2021, Viral immunology,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
January 2010, Antiviral therapy,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
March 2004, HIV medicine,
S Kostense, and F M Raaphorst, and D W Notermans, and J Joling, and B Hooibrink, and N G Pakker, and S A Danner, and J M Teale, and F Miedema
January 2018, International journal of chronic diseases,
Copied contents to your clipboard!